Form 4: Apogee Therapeutics CEO Michael Henderson Sells Shares Under 10b5-1 Trading Plan

Apogee Therapeutics CEO Michael Henderson sold shares of common stock on September 4, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Henderson, CEO of Apogee Therapeutics, sold shares of the company's common stock on September 4, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 25, 2023.
• A total of 25,641 shares were sold at a weighted average price of $47.28, and 14,359 shares were sold at a weighted average price of $48.23.
• Following these transactions, Henderson beneficially owns 1,394,487 shares of Apogee Therapeutics.
• The sales were conducted in multiple transactions within price ranges of $46.95 to $47.855 and $47.95 to $48.54.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as it's a factual report of transactions.

Industry Context

Executive stock sales are a common occurrence, and the use of 10b5-1 trading plans allows insiders to sell shares without being accused of trading on non-public information. The market will likely interpret this sale in the context of the company's overall performance and future prospects.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, depending on how the market interprets the CEO's actions.
• The sale does not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates